Wells Fargo
EDIT icon

Wells Fargo’s Editas Medicine EDIT Stock Holding History

Wells Fargo’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Buy
120,753
+18,723
+18% +$54.7K ﹤0.01% 4791
2026
Q1 		$252K Sell
102,030
-60,714
-37% -$128K ﹤0.01% 4571
2025
Q4 		$334K Buy
162,744
+34,432
+27% +$99.4K ﹤0.01% 4769
2025
Q3 		$445K Sell
128,312
-7,696
-6% -$21.5K ﹤0.01% 4387
2025
Q2 		$299K Sell
136,008
-15,174
-10% -$24.8K ﹤0.01% 4500
2025
Q1 		$175K Sell
151,182
-35,147
-19% -$51.7K ﹤0.01% 4795
2024
Q4 		$237K Sell
186,329
-318,436
-63% -$811K ﹤0.01% 4691
2024
Q3 		$1.72M Buy
504,765
+321,888
+176% +$1.4M ﹤0.01% 3154
2024
Q2 		$854K Buy
182,877
+54,025
+42% +$305K ﹤0.01% 3591
2024
Q1 		$956K Buy
128,852
+12,328
+11% +$102K ﹤0.01% 3489
2023
Q4 		$1.18M Sell
116,524
-94,072
-45% -$826K ﹤0.01% 3320
2023
Q3 		$1.64M Sell
210,596
-5,722
-3% -$49.1K ﹤0.01% 2945
2023
Q2 		$1.78M Buy
216,318
+1,182
+0.5% +$10.3K ﹤0.01% 3012
2023
Q1 		$1.56M Sell
215,136
-56,868
-21% -$506K ﹤0.01% 3070
2022
Q4 		$2.41M Buy
272,004
+82,438
+43% +$905K ﹤0.01% 2648
2022
Q3 		$2.32M Buy
189,566
+3,731
+2% +$58.1K ﹤0.01% 2613
2022
Q2 		$2.2M Buy
185,835
+18,239
+11% +$244K ﹤0.01% 2711
2022
Q1 		$3.19M Buy
167,596
+15,609
+10% +$290K ﹤0.01% 2856
2021
Q4 		$4.04M Sell
151,987
-68,436
-31% -$2.36M ﹤0.01% 2790
2021
Q3 		$9.05M Buy
220,423
+22,207
+11% +$1.22M ﹤0.01% 2300
2021
Q2 		$11.2M Buy
198,216
+56,850
+40% +$2.1M ﹤0.01% 2135
2021
Q1 		$5.94M Sell
141,366
-9,863
-7% -$562K ﹤0.01% 2684
2020
Q4 		$10.6M Buy
151,229
+66,908
+79% +$2.75M ﹤0.01% 2041
2020
Q3 		$2.37M Buy
84,321
+13,532
+19% +$441K ﹤0.01% 3181
2020
Q2 		$2.09M Buy
70,789
+13,727
+24% +$359K ﹤0.01% 3229
2020
Q1 		$1.13M Buy
57,062
+1,547
+3% +$39K ﹤0.01% 3470
2019
Q4 		$1.64M Sell
55,515
-1,506
-3% -$37.6K ﹤0.01% 3499
2019
Q3 		$1.3M Sell
57,021
-4,220
-7% -$105K ﹤0.01% 3651
2019
Q2 		$1.51M Buy
61,241
+2,212
+4% +$52.8K ﹤0.01% 3564
2019
Q1 		$1.44M Sell
59,029
-9,987
-14% -$226K ﹤0.01% 3608
2018
Q4 		$1.57M Sell
69,016
-685
-1% -$18.6K ﹤0.01% 3479
2018
Q3 		$2.22M Sell
69,701
-9,432
-12% -$305K ﹤0.01% 3330
2018
Q2 		$2.83M Buy
79,133
+22,480
+40% +$796K ﹤0.01% 3170
2018
Q1 		$1.88M Buy
56,653
+7,862
+16% +$280K ﹤0.01% 3433
2017
Q4 		$1.5M Buy
48,791
+3,415
+8% +$86K ﹤0.01% 3599
2017
Q3 		$1.09M Buy
45,376
+14,646
+48% +$279K ﹤0.01% 3785
2017
Q2 		$515K Sell
30,730
-34,250
-53% -$617K ﹤0.01% 4203
2017
Q1 		$1.45M Buy
64,980
+15,361
+31% +$318K ﹤0.01% 3459
2016
Q4 		$806K Buy
49,619
+47,336
+2,073% +$718K ﹤0.01% 3860
2016
Q3 		$31K Sell
2,283
-2,000
-47% -$41K ﹤0.01% 5477
2016
Q2 		$105K Buy
4,283
+2,309
+117% +$77.9K ﹤0.01% 4792
2016
Q1 		$68K Buy
+1,974
New +$51.9K ﹤0.01% 5091

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Wells Fargo's EDIT Position: Q2 2026 in Review

Wells Fargo increased its Editas Medicine (EDIT) stake by 18% in Q2 2026, buying an estimated $54.7K and bringing the position to 120,753 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #4791.

Wells Fargo first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $11.2M in Q2 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Wells Fargo held 120,753 shares of Editas Medicine worth $391K as of Q2 2026.
  • Wells Fargo bought 18,723 Editas Medicine shares in Q2 2026, an estimated $54.7K.
  • Editas Medicine made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4791 holding.
  • Wells Fargo first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Wells Fargo's Editas Medicine position peaked at $11.2M in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.